ストックスクリーナーアプリを入手
84.07
1.08%
-0.92
アフターアワーズ：
84.13
0.06
+0.07%
Merck Co Inc (MRK) 最新ニュース
Elfun Trusts Exits Merck & Co Inc, Impacting Portfolio by -1.85% - ca.finance.yahoo.com
Summit, Akeso Lung Cancer Drug Rivals Merck’s KeytrudaSummit Therapeutics (NASDAQ:SMMT) - Benzinga
Human Growth Hormone Market to Hit USD 18.25 Billion by 2032, Driven by Expanding Therapeutic Applications and Biotech Advances – SNS Insider - GlobeNewswire Inc.
Rising as One, Shining as Many - GlobeNewswire Inc.
Merck & Co., Inc. shares fall 1.73% intraday after Bernstein reiterates Neutral rating, lowering target price to EUR 138. - AInvest
Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025 - Business Wire
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Merck shares snapped six-session winning streak (NYSE:MRK) - Seeking Alpha
Skyhawk’s small-molecule RNA efforts draw Merck KGaA in $2B deal - BioWorld MedTech
Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds - Business Wire
Skyhawk Flies High With Another Big Pharma, Getting Up To $2bn In Merck KGaA Deal - insights.citeline.com
Merck KGaA Signs $2 Billion Neurology Drug Pact With Skyhawk - Bloomberg.com
Merck: Shares Bucking The Gardasil Problem, Hiking My Price Target - Seeking Alpha
Q3 EPS Estimates for Merck & Co., Inc. Cut by Zacks Research - Defense World
Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration - MSN
Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial - MSN
Merck Stock: Buy The Weakness (NYSE:MRK) - Seeking Alpha
Austria Accepts Merck Commitments After ‘Predatory Pricing’ Undermined Generics - insights.citeline.com
Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness - MSN
The Zacks Analyst Blog Highlights Merck, Palo Alto Networks, Freeport-McMoRan and Espey - Yahoo Finance
Top Analyst Reports for Merck, Palo Alto & Freeport - Yahoo Finance
10 Stocks Jim Cramer Discussed As He Questioned Official Data - Insider Monkey
Livestock Monitoring Company Evaluation Report 2025 | Merck & Co., GEA Group, and DeLaval Drive Global Innovations Across Biopharma, Process Technology, and Dairy Farming Automation - Yahoo Finance
Stock Watch: Sanofi And Merck Temper Big Pharma Q2 Earnings Cheer - insights.citeline.com
Goldman Sachs Slashes PT on Merck & Co. (MRK) to $94 From $99, Keeps a Buy Rating - MSN
What's Going On With Merck Stock Tuesday?Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE) - Benzinga
IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal - Reuters
Merck to Begin Phase 3 Trials for Investigational Monthly HIV Prevention Pill - MSN
Merck KGaA Plans $4 Billion Bond Sale to Fund SpringWorks Therapeutics Acquisition - Bloomberg.com
Merck & Co Stock Ends Higher After Volatile Session - thekhabrilal
Analysts Set Merck & Co., Inc. (NYSE:MRK) Price Target at $107.44 - Defense World
Critical Review: Merck & Co., Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) - Defense World
The departure of senior executives from Merck & Co Inc and Novartis triggered a "chain reaction". Heng Rui and Wise had intensive personnel changes in local pharmaceutical companies. Inventory of personnel changes in October. - 富途牛牛
Merck & Co. (MRK) Divests Surface Solutions for €665 million - MSN
Goldman Sachs Reduced the PT on Merck & Co., Inc. (MRK), Kept a Buy Rating - MSN
Verona’s COPD Launch Success Sealed Merck Buyout Interest - insights.citeline.com
Merck & Co Inc Options Trading: September 26th Expiration - AInvest
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know - Yahoo Finance
United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda - Yahoo Finance
1.99%
0.56%
大文字化:
|
ボリューム (24 時間):